SCHEMBL4093310

SCHEMBL4093310

CCOC(=N)c1ccc2[nH]nc(-c3ccc4nc(OC)ccc4c3)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 4/20 0.39
MAP2K4 P45985 6/20 0.38
MAPK1 P28482 4/20 0.38
MAPKAPK3 Q16644 4/20 0.38
MAPK6 Q16659 4/20 0.38
MAPKAPK2 P49137 3/20 0.38
MAPKAPK5 Q8IW41 2/20 0.38
TTK P33981 3/20 0.37
MAPK8 P45983 2/20 0.37
ADORA1 P30542 1/20 0.36
CDK4 P11802 1/20 0.36
CCNA2 P20248 1/20 0.36
CCND1 P24385 1/20 0.36
CDK2 P24941 1/20 0.36
CCND3 P30281 1/20 0.36
KDR P35968 1/20 0.36
HPGD P15428 1/20 0.35
DGAT1 O75907 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
SIRT1 Q96EB6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043448 0.85 BTK (0.45) FLT3MAP2K4MAPK1MAPKAPK3MAPK6
Hydrochloric Acid SCHEMBL5397824 0.84 BTK (0.44) FLT3MAP2K4MAPK1MAPKAPK3MAPK6
Hydrochloric Acid SCHEMBL4083323 0.84 BTK (0.44) FLT3MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL4083929 0.83 BTK (0.43) FLT3MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL4084769 0.83 TTK (0.48) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
Hydrochloric Acid SCHEMBL4083919 0.81 MAP2K4 (0.47) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
Hydrochloric Acid SCHEMBL4090684 0.80 MAP2K4 (0.42) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
Hydrochloric Acid SCHEMBL4079950 0.80 MAP2K4 (0.42) FLT3MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL13811896 0.79 ADORA1 (0.38) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL4079542 0.78 TTK (0.43) FLT3MAP2K4MAPK1MAPKAPK3MAPK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 FLT3 1140/4885MAP2K4 358/4885MAPK1 171/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 FLT3 1162/4885MAP2K4 357/4885MAPK1 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.